# Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

> **NCT04145037** · PHASE1,PHASE2 · TERMINATED · sponsor: **AVROBIO** · enrollment: 8 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** AVR-RD-02

## Key facts

- **NCT ID:** NCT04145037
- **Lead sponsor:** AVROBIO
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-30
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** This study was voluntarily terminated by the sponsor to halt development and was not based on any safety or medical reasons.
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145037, "Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04145037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*